4-甲酰氯苯硼酸 | 332154-57-1

• 物质功能分类: 化学试剂 - 有机试剂 - 硼酸
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-甲酰氯苯硼酸
• 中文别名: 4-氯羰基苯硼酸酐；4-甲酰氯基苯硼酸；4-氯甲酰基苯基硼酐；(4-(氯羰基)苯基)硼酸
• 英文名称: (4-(chlorocarbonyl)phenyl)boronic acid
• 英文别名: 4-Chlorocarbonylphenylboronic acid；(4-carbonochloridoylphenyl)boronic acid
• CAS: 332154-57-1
• 化学式: C₇H₆BClO₃
• mdl: MFCD08062416
• 分子量: 184.387
• InChiKey: ARKQVAQLGLIPAU-UHFFFAOYSA-N

物化性质

• 熔点：
  >300℃
• 沸点：
  350.9±44.0 °C(Predicted)
• 密度：
  1.39±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.63
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xn
• 安全说明：
  S26,S36
• 危险类别码：
  R20/21/22,R36/37/38
• 海关编码：
  2931900090
• 包装等级：
  III
• 危险类别：
  8
• 危险性防范说明：
  P280,P305+P351+P338,P310
• 危险品运输编号：
  3261
• 危险性描述：
  H314
• 储存条件：
  室温

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 4-Chlorocarbonylphenylboronic anhydride
Synonyms: 4-(Oxoboryl)benzoyl chloride

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 4-Chlorocarbonylphenylboronic anhydride
CAS number: 332154-57-1

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H4BClO2
Molecular weight: 166.4

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-甲酰氯苯硼酸 在 四(三苯基膦)钯 碳酸氢钠 、 三乙胺 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 水 为溶剂， 反应 30.0h， 生成 2-(3-((7-(4-(4-(2-((tert-butyldimethylsilyl)oxy)ethyl)piperazine-1-carbonyl)phenyl)quinazolin-4-yl)amino)-1H-pyrazol-5-yl)-N-(3-fluorophenyl)acetamide
  参考文献：
  名称：

  [EN] AURORA KINASE INHIBITORS
  [FR] INHIBITEUR DE L'AURORA KINASE

  摘要：

  公开号：

  WO2009111028A8
• 作为产物：
  描述：

  4-甲苯硼酸 在 sodium hydroxide 、 potassium permanganate 、 氯化亚砜 作用下， 以 水 为溶剂， 反应 72.0h， 生成 4-甲酰氯苯硼酸
  参考文献：
  名称：

  [EN] DIARYLUREA DERIVATIVES AND THEIR USE AS CHLORIDE CHANNEL BLOCKERS
  [FR] DERIVES DE DIARYLUREE ET LEUR UTILISATION COMME BLOQUEURS DE CANAUX CHLORURE

  摘要：

  公开号：

  WO2004022529A3

文献信息

• Ataxia Telengiectasia And Rad3-Related (ATR) Protein Kinase Inhibitors
  申请人：Atrin Pharmaceuticals LLC

  公开号：US20160102104A1

  公开（公告）日：2016-04-14

  A macrocyclic compound having the structure of Formula (A), wherein each of R 1 and R 2 is independently (i) a 5-6 membered monocyclic aromatic ring containing 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or (ii) an 8-10 membered bicyclic aromatic ring containing 0-6 heteroatoms independently selected from nitrogen, oxygen, or sulfur. Each R 1 and R 2 may independently be substituted by 0, 1, 2, 3, or 4 substituents. Z 1 represents a covalent bond, an atom, or a functional group comprising a grouping of atoms, wherein the grouping of atoms includes at least one heteroatom selected from the group consisting of N, O, P, and S. Also, Z 1 may represent (i) a 5-6 membered monocyclic aromatic ring containing 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or (ii) an 8-10 membered bicyclic aromatic ring containing 0-6 heteroatoms independently selected from nitrogen, oxygen, or sulfur. Z 2 represents a covalent bond, an atom, or a functional group comprising a grouping of atoms, wherein the grouping of atoms includes at least one heteroatom selected from the group consisting of N, O, P, and S. Variable v is an integer having a value of 1 or 0. T is a carbon atom, a nitrogen atom, a sulfur atom, or an oxygen atom. L is a linking group covalently bonded to T when v has a value of 1 or L is covalently bonded to R 1 when v has a value of 0. L is covalently bonded to Z 2 when Z 2 is an atom or a functional group comprising grouping of atoms and/or L is covalently bonded to R 2 when Z 2 is a covalent bond. Each of R 3 , R 4 and R 5 may be the same as or different from each other and each is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, aralkyl, and heteraralkyl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, aralkyl, and heteraralkyl is optionally substituted by one or more suitable substituents.

  具有Formula (A)结构的大环化合物，其中R1和R2中的每一个独立地是(i) 包含0-4个从氮、氧或硫中独立选择的杂原子的5-6成员单环芳香环；或(ii) 包含0-6个从氮、氧或硫中独立选择的杂原子的8-10成员双环芳香环。每个R1和R2可以独立地被0、1、2、3或4个取代基取代。Z1代表共价键、原子或包含来自N、O、P和S组成的杂原子中至少一个的原子团的官能团，Z1也可以表示(i) 包含0-4个从氮、氧或硫中独立选择的杂原子的5-6成员单环芳香环；或(ii) 包含0-6个从氮、氧或硫中独立选择的杂原子的8-10成员双环芳香环。Z2代表共价键、原子或包含来自N、O、P和S组成的杂原子中至少一个的原子团的官能团，变量v是一个值为1或0的整数。T是碳原子、氮原子、硫原子或氧原子。当v的值为1时，L是与T共价键合的连接基，或当v的值为0时，L与R1共价键合。当Z2是原子或包含原子团的官能团时，L与Z2共价键合，和/或当Z2是共价键时，L与R2共价键合。R3、R4和R5中的每一个可以相同也可以不同，每个独立地从氢、烷基、烯基、炔基、环烷基、环烯基、杂环烷基、芳基、杂芳基、芳基烷基和杂芳基中选择，其中每个烷基、烯基、炔基、环烷基、环烯基、杂环烷基、芳基、杂芳基、芳基烷基和杂芳基可以选择性地被一个或多个适当的取代基取代。
• [EN] INDOLINONE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS<br/>[FR] COMPOSÉS D'INDOLINONE SERVANT D'INHIBITEURS DE MAP4K1
  申请人：ICHNOS SCIENCES S A

  公开号：WO2020070331A1

  公开（公告）日：2020-04-09

  The present disclosure is directed to compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein ring A, ring C, X1, X2, L1, R1, R2, R3, R4, R5, R6, R7, m and n are as defined herein, which are useful as MAP4K1 inhibitors, processes for their preparation, pharmaceutical compositions comprising the compounds, and the use of the compounds or the compositions in the treatment or prevention of various diseases, conditions and/or disorders mediated by MAP4K1.

  本公开涉及式(I)的化合物及其药用盐，其中环A、环C、X1、X2、L1、R1、R2、R3、R4、R5、R6、R7、m和n如本文所定义，这些化合物可用作MAP4K1抑制剂，其制备方法，包含这些化合物的药物组合物，以及这些化合物或组合物在治疗或预防由MAP4K1介导的各种疾病、症状和/或紊乱中的用途。
• ＩＲＥ−１αインヒビター
  申请人：マンカインド コーポレ−ション

  公开号：JP2015214548A

  公开（公告）日：2015-12-03

  【課題】インビトロでイノシトール要求性酵素1（IRE-1α活性）を直接阻害する化合物、それらのプロドラッグ及び薬学的に許容可能な塩の提供。【解決手段】式（Ａ）で表される化合物。[Ｒ３及びＲ４はＨ等；Ｑ５〜Ｑ８はこれらが結合しているベンゼン環と一緒になってベンゾ縮合環を形成し、Ｑ５〜Ｑ８のうち少なくとも1つは、Ｎ、Ｓ、及びＯより選択されるヘテロ原子]【選択図】なし

  这是一个关于直接抑制肝细胞内胞外信号调节激酶1（IRE-1α）活性的化合物、它们的前药以及药学上可接受的盐的提供的问题。这些化合物由式（A）表示。[R3和R4是H等；Q5〜Q8与它们结合形成苯环并形成苯并环，Q5〜Q8中至少有一个是从N、S和O中选择的杂原子]【选择图】无
• [EN] SUBSTITUTED 1,6-NAPHTHYRIDINES<br/>[FR] 1,6-NAPHTYRIDINES SUBSTITUÉES
  申请人：HOFFMANN LA ROCHE

  公开号：WO2014079787A1

  公开（公告）日：2014-05-30

  The present invention relates to the use of compounds of general formula (I) wherein R' is hydrogen or lower alkyl; R1 is halogen, lower alkyl, cycloalkyl or cyano; or is phenyl, optionally substituted by one to three substituents, selected from lower alkyl, lower alkyl substituted by halogen, lower alkoxy, lower alkoxy substituted by halogen, halogen, cyano, hydroxy, C(O)-NH-lower alkyl, CH2-C(O)-NH-lower alkyl, CH2-NH-C(O)-lower alkyl, CH2NH2, S(O)2CH3, S(O)2N(CH3)2, or by heterocycloalkyl groups; or is pyrazol-1, 4 or 5-yl, optionally substituted by lower alkyl; or is thiazol-5-yl, optionally substituted by one or two lower alkyl groups; or is pyridine 2, 3 or 4-yl, optionally substituted by lower alkyl, lower alkoxy, halogen or N(CH3)2; or is 3,6-dihydro-2H-pyran; or is benzo[d][1,3]dioxol-5-yl; or is 2,3-dihydrobenzo[b][1,4]dioxin-6-yl; R2 is hydrogen, lower alkyl or lower alkyl substituted by alkoxy; R3 is hydrogen, lower alkyl, lower alkyl substituted by halogen, lower alkyl substituted by hydroxy, NH-S(O)2-CH3, -(CH2)m-O-lower alkyl or -(CH2)n-S(O)2-CH3; or is -(CR2)n-phenyl, optionally substituted by -S(O)2CH3 or lower alkoxy; or is -(CH2)n-heterocycloalkyl, optionally substituted by lower alkyl and =O; or is -(CH2)n-heteroaryl, optionally substituted by one or two lower alkyl groups; or is -(CH2)n-cycloalkyl, optionally substituted by cyano; or R2 and R3 form together with the N atom to which they are attached a heterocyclic ring, selected from morpholine, piperidine, 1, 1-dioxo-thiomorpholine or piperazine which may be substituted by lower alkyl or C(O)O-lower alkyl, or may form a pyrrolidine ring, optionally substituted by hydroxy; R is independently from n hydrogen or lower alkyl; n is 0, 1, 2, 3; m is 2; or to a pharmaceutically acceptable acid addition salt, to a racemic mixture or to its corresponding enantiomer and/or optical isomers thereof, for the treatment of schizophrenia, obsessive-compulsive personality disorder, depression, bipolar disorders, anxiety disorders, normal aging, epilepsy, retinal degeneration, traumatic brain injury, spinal cord injury, post-traumatic stress disorder, panic disorder, Parkinson's disease, dementia, Alzheimer's disease, mild cognitive impairment, chemotherapy-induced cognitive dysfunction ("chemobrain"), Down syndrome, autism spectrum disorders, hearing loss, tinnitus, spinocerebellar ataxia, amyotrophic lateral sclerosis, multiple sclerosis, Huntington's disease, stroke, and disturbances due to radiation therapy, chronic stress, optic neuropathy or macular degeneration, or abuse of neuro-active drugs selected from alcohol, opiates, methamphetamine, phencyclidine or cocaine.

  本发明涉及使用一般式（I）的化合物，其中R'是氢或较低的烷基；R1是卤素、较低的烷基、环烷基或氰基；或者是苯基，可选择地被一个到三个取代基取代，所述取代基选自较低的烷基、被卤素取代的较低烷基、较低的烷氧基、被卤素取代的较低烷氧基、卤素、氰基、羟基、C(O)-NH-较低烷基、CH2-C(O)-NH-较低烷基、CH2-NH-C(O)-较低烷基、CH2NH2、S(O)2CH3、S(O)2N(CH3)2，或者是由杂环烷基组成的基团；或者是吡唑-1、4或5-基，可选择地被较低烷基取代；或者是噻唑-5-基，可选择地被一个或两个较低烷基基团取代；或者是吡啶-2、3或4-基，可选择地被较低烷基、较低烷氧基、卤素或N(CH3)2取代；或者是3,6-二氢-2H-吡喃；或者是苯并[d][1,3]二噁嗪-5-基；或者是2,3-二氢苯并[b][1,4]二噁烷-6-基；R2是氢、较低烷基或被烷氧基取代的较低烷基；R3是氢、较低烷基、被卤素取代的较低烷基、被羟基取代的较低烷基、NH-S(O)2-CH3、-(CH2)m-O-较低烷基或-(CH2)n-S(O)2-CH3；或者是-(CR2)n-苯基，可选择地被-S(O)2CH3或较低烷氧基取代；或者是-(CH2)n-杂环烷基，可选择地被较低烷基和=O取代；或者是-(CH2)n-杂芳基，可选择地被一个或两个较低烷基基团取代；或者是-(CH2)n-环烷基，可选择地被氰基取代；或者R2和R3与它们连接的N原子一起形成一个杂环环，所述杂环环选自吗啉、哌啶、1,1-二氧代-硫代吗啉或哌嗪，可被较低烷基或C(O)O-较低烷基取代，或者可形成一个吡咯烷环，可选择地被羟基取代；R独立于n是氢或较低烷基；n为0、1、2、3；m为2；或者是药学上可接受的酸盐，或者是外消旋混合物，或者是其对应的对映体和/或光学异构体，用于治疗精神分裂症、强迫性人格障碍、抑郁症、躁郁症、焦虑症、正常衰老、癫痫、视网膜退化、创伤性脑损伤、脊髓损伤、创伤后应激障碍、恐慌障碍、帕金森病、痴呆症、阿尔茨海默病、轻度认知障碍、化疗诱导的认知功能障碍（“化疗脑”）、唐氏综合征、自闭症谱系障碍、听力丧失、耳鸣、脊髓小脑共济失调、肌萎缩侧索硬化、多发性硬化症、亨廷顿病、中风，以及由放射治疗、慢性应激、视神经病变或黄斑变性引起的干扰，或者由酒精、阿片类药物、甲基苯丙胺、芬太尼或可卡因等神经活性药物的滥用引起的干扰。
• Discovery of Aryl Benzoyl Hydrazide Derivatives as Novel Potent Broad-Spectrum Inhibitors of Influenza A Virus RNA-Dependent RNA Polymerase (RdRp)
  作者：Xinjin Liu、Jinsen Liang、Yongshi Yu、Xin Han、Lei Yu、Feifei Chen、Zhichao Xu、Qi Chen、Mengyu Jin、Chune Dong、Hai-Bing Zhou、Ke Lan、Shuwen Wu

  DOI：10.1021/acs.jmedchem.1c01257

  日期：2022.3.10

  exhibited potent inhibitory activity against the avian H5N1 flu strain with EC50 values ranging from 0.009 to 0.034 μM. Moreover, compound 11q exhibited nanomolar antiviral effects against both the H1N1 virus and Flu B virus and possessed good oral bioavailability and inhibitory activity against influenza A virus in a mouse model. Preliminary mechanistic studies suggested that these compounds exert anti-influenza

  甲型流感病毒具有较高的抗原性转变，而获批的抗流感药物极为有限，这使得开发用于临床治疗和预防流感暴发的新型抗流感药物势在必行。在此，我们报告了一系列新型芳基苯甲酰肼类似物作为有效的抗流感药物。特别地，类似物10b、10c、10g、11p和11q表现出对禽H5N1流感病毒株的有效抑制活性，EC 50值范围为0.009至0.034 μM。此外，化合物11q对 H1N1 病毒和乙型流感病毒均表现出纳摩尔级抗病毒作用，并在小鼠模型中具有良好的口服生物利用度和对甲型流感病毒的抑制活性。初步机制研究表明，这些化合物主要通过与 RNA 依赖性 RNA 聚合酶 (RdRp) 的 PB1 亚基相互作用来发挥抗流感病毒作用。这些结果表明，11q有可能成为对抗季节性流感和流感大流行的有效临床候选药物。